|By PR Newswire||
|December 10, 2013 09:50 PM EST||
MALVERN, Pa., Dec. 10, 2013 /PRNewswire/ -- Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013.
Recognized for his strategic capabilities, Mr. Higgins has over 30 years of domestic and international pharmaceutical industry experience. He is currently a Senior Advisor to Blackstone Healthcare Partners, the dedicated healthcare team of The Blackstone Group, where he focuses on product-based healthcare acquisitions. Prior to joining Blackstone, he served as Chairman of the Board of Management of Bayer HealthCare AG and Chairman & CEO of Enzon Pharmaceuticals.
Commenting on today's announcement, Roger Kimmel, Chairman of Endo's Board, said, "We are pleased to welcome Art Higgins to the Endo Board. Given the depth and breadth of his healthcare and pharmaceutical industry experience, we are confident that his unique insight and international perspective will be valuable resources as Endo continues its transformation into a more focused global specialty healthcare company."
Mr. Higgins stated, "I believe that Endo has a differentiated strategy and a management team that can execute this strategy well. Endo is well-positioned to continue to offer products that make a difference in the lives of patients while generating superior growth and returns for shareholders. I am honored to join the Board of a fast-growing leader in the healthcare industry, and look forward to contributing to Endo's momentum."
Mr. Kimmel added, "On behalf of the Board of Directors, I would like to extend our sincere appreciation to Joe Scodari for his valuable and tireless contributions to the Board over many years and wish him the best in his future endeavors."
Mr. Scodari stated, "It has been a pleasure to serve on the Endo Board of Directors for the past five years. I am confident that Endo has the right leadership and a clear vision in place for its next phase of growth, and I wish the company continued success."
Biography of Arthur J. Higgins
Art Higgins, 57, has over 30 years of experience in the pharmaceutical industry. He is currently a Senior Advisor to Blackstone Healthcare Partners, the dedicated healthcare team of The Blackstone Group, where he focuses on product-based healthcare acquisitions. Prior to that, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG, a developer and manufacturer of human and animal health products, and Chairman of the Bayer HealthCare Executive Committee. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to joining Enzon Pharmaceuticals, Mr. Higgins spent 14 years with Abbott Laboratories, including serving as President of the Pharmaceutical Products Division from 1998 to 2001.
Mr. Higgins currently serves on the Boards of Ecolab, Inc. Resverlogix Corp. and Zimmer Holdings, Inc. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins has a B.S. in biochemistry from Strathclyde University in Glasgow, Scotland.
Endo Health Solutions Inc. (Endo) is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services, each providing quality products to our customers while improving the lives of patients. Through our operating companies – AMS, Endo Pharmaceuticals, HealthTronics and Qualitest – Endo is dedicated to finding solutions for the unmet needs of patients. Learn more at www.endo.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Health Solutions